Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 2.35 | 1.9 |
NAV | ₹16.01 | ₹38.63 |
Fund Started | 18 Oct 2021 | 25 Jun 2018 |
Fund Size | ₹220.85 Cr | ₹5507.52 Cr |
Exit Load | Exit load of 0.50%, if redeemed within 3 months. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 14.49% | 20.48% |
3 Year | 22.99% | 29.17% |
5 Year | - | 23.50% |
1 Year
3 Year
5 Year
Equity | 99.70% | 96.99% |
Cash | 0.30% | 3.01% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 15.18% |
Divi's Laboratories Ltd. | 9.12% |
Max Healthcare Institute Ltd. | 5.42% |
Lupin Ltd. | 5.40% |
Apollo Hospitals Enterprise Ltd. | 5.19% |
Cohance Lifesciences Ltd. | 4.84% |
Aurobindo Pharma Ltd. | 3.93% |
Torrent Pharmaceuticals Ltd. | 3.91% |
Aster DM Healthcare Ltd. | 3.15% |
Mankind Pharma Ltd. | 3.04% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 12.66% |
Dr. Reddy's Laboratories Ltd. | 9.66% |
Divi's Laboratories Ltd. | 9.03% |
Cipla Ltd. | 7.85% |
Aurobindo Pharma Ltd. | 6.34% |
Alkem Laboratories Ltd. | 4.12% |
Zydus Lifesciences Ltd. | 4.01% |
Lupin Ltd. | 3.98% |
Gland Pharma Ltd. | 3.95% |
Syngene International Ltd. | 2.46% |
Name | Dhimant Shah | Dharmesh Kakkad |
Start Date | 01 Dec 2022 | 23 Feb 2021 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 18 Oct 2021 | 25 Jun 2018 |
Description
Launch Date